<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02956356</url>
  </required_header>
  <id_info>
    <org_study_id>SATIOSTAT acute effects</org_study_id>
    <nct_id>NCT02956356</nct_id>
  </id_info>
  <brief_title>Acute Effects of SATIOSTAT Ingestion on Satiation Hormones, Gastric Emptying, Subjective Feelings of Appetite and Energy Intake</brief_title>
  <official_title>Acute Effects of SATIOSTAT Ingestion on Satiation Hormones, Gastric Emptying, Subjective Feelings of Appetite and Energy Intake</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      SATIOSTAT is a composition comprising a specific dietary fibre component (a mixture of&#xD;
      hydrocolloids with excellent safety profiles and a long history of use in humans) and a lipid&#xD;
      component (long-chain fatty acids). The goal of this combination is to achieve long-acting&#xD;
      delivery of long-chain fatty acids to the intestinal lining, triggering the sustained release&#xD;
      of satiety-signals from intestinal cells, and consequently reducing appetite and lowering&#xD;
      food intake in humans.&#xD;
&#xD;
      Effects of acute ingestion of SATIOSTAT vs. a control will be examined. On a first and second&#xD;
      study day, volunteers receive a preload of either SATIOSTAT or a control and then an oral&#xD;
      glucose load of 75g enriched with C13 sodium acetate. Gastric emptying will be measured by&#xD;
      means of a breath test, and insulin, glucose and satiation hormones will be assessed. On the&#xD;
      third and fourth study day, volunteers receive a preload of either SATIOSTAT or a control and&#xD;
      are then presented a test meal. Total calorie intake is measured as well as subjective&#xD;
      feelings of satiation. In addition satiation hormones are measured.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Actual">February 2018</completion_date>
  <primary_completion_date type="Actual">February 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute effects of SATIOSTAT on gastrointestinal (GI) peptide release measured by ELISA</measure>
    <time_frame>changes from baseline to three hours after treatment</time_frame>
    <description>measured by commercially available ELISA (enzyme-linked immunosorbent assay )-kits</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute effects of SATIOSTAT on glucose tolerance measured by oral glucose tolerance test</measure>
    <time_frame>changes from baseline to three hours after treatment</time_frame>
    <description>measured with oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute effects of SATIOSTAT on gastric emptying measured by 13C-sodium-acetate breath test</measure>
    <time_frame>changes from baseline to four hours after treatment</time_frame>
    <description>measured by 13C-sodium-acetate breath test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute effects of SATIOSTAT on subjective feelings of hunger and satiety measured by visual analogue scales</measure>
    <time_frame>changes from baseline to three hours after treatment</time_frame>
    <description>measured by visual analogue scales</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute effects of SATIOSTAT on subsequent calorie intake measured by calorie intake from a test meal</measure>
    <time_frame>changes from baseline to two hours after treatment</time_frame>
    <description>calorie intake from a test meal will be assessed</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Control treatment + oral glucose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control treatment as preload and then an oral glucose load of 75g enriched with C13 sodium acetate (for determination of gastric emptying rates)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SATIOSTAT treatment + oral glucose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SATIOSTAT treatment as preload and then an oral glucose load of 75g enriched with C13 sodium acetate (for determination of gastric emptying rates)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control treatment + meal intake</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control treatment as preload followed by a test meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SATIOSTAT treatment + meal intake</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SATIOSTAT treatment as preload followed by a test meal</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Control treatment + oral glucose</intervention_name>
    <description>Control granulates (maize starch and long-chain fatty acids) with powder; 75g oral glucose load</description>
    <arm_group_label>Control treatment + oral glucose</arm_group_label>
    <other_name>The energy content of one single bottle control is 138kcal and contains 7.6g fat, 11.1g carbohydrates and 3.9g protein.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>SATIOSTAT treatment + oral glucose</intervention_name>
    <description>SATIOSTAT granulates (hydrocolloids (fibers) and long-chain fatty acids) with powder; 75g oral glucose load</description>
    <arm_group_label>SATIOSTAT treatment + oral glucose</arm_group_label>
    <other_name>The energy content of one single bottle SATIOSTAT is 138kcal and contains 10.5g fat, 6.4g carbohydrates and 3.9g protein.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Control treatment + meal intake</intervention_name>
    <description>Control granulates (maize starch and long-chain fatty acids) with powder; test meal (ham sandwiches: 50g bread, 10g butter, 29g ham (pork); 247 kcal/sandwich) and tap water)</description>
    <arm_group_label>Control treatment + meal intake</arm_group_label>
    <other_name>The energy content of one single bottle control is 138kcal and contains 7.6g fat, 11.1g carbohydrates and 3.9g protein.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>SATIOSTAT treatment + meal intake</intervention_name>
    <description>SATIOSTAT granulates (hydrocolloids (fibers) and long-chain fatty acids) with powder; test meal (ham sandwiches: 50g bread, 10g butter, 29g ham (pork); 247 kcal/sandwich) and tap water)</description>
    <arm_group_label>SATIOSTAT treatment + meal intake</arm_group_label>
    <other_name>The energy content of one single bottle SATIOSTAT is 138kcal and contains 10.5g fat, 6.4g carbohydrates and 3.9g protein.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Obese volunteers (BMI &gt; 30kg/m2)&#xD;
&#xD;
          -  Otherwise healthy&#xD;
&#xD;
          -  Informed Consent as documented by signature (Appendix Informed Consent Form)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Food allergies, food intolerance&#xD;
&#xD;
          -  Evidence of relevant cardiovascular, pulmonary, renal, hepatic, pancreatic,&#xD;
             gastrointestinal, metabolic, endocrinological, neurological, psychiatric or other&#xD;
             diseases at screening&#xD;
&#xD;
          -  Chronic or clinically relevant acute infections&#xD;
&#xD;
          -  Clinically relevant abnormalities in chemical, haematological or any other laboratory&#xD;
             parameters&#xD;
&#xD;
          -  Participation in drug trials within 2 months before start of the study&#xD;
&#xD;
          -  Neurological or psychiatric disease or drug or alcohol abuse, which would interfere&#xD;
             with the subjects proper completion of the protocol assignment&#xD;
&#xD;
          -  Pregnancy: although no contraindication pregnancy might influence metabolic state.&#xD;
             Women who are pregnant or have the intention to become pregnant during the course of&#xD;
             the study are excluded. In female participants of childbearing age not using safe&#xD;
             contraception (oral, injectable, or implantable contraceptives, or intrauterine&#xD;
             contraceptive devices) a urine pregnancy test is carried out upon screening.&#xD;
&#xD;
          -  Antibiotic therapy within the last 3 months before inclusion&#xD;
&#xD;
          -  Substance abuse, alcohol abuse&#xD;
&#xD;
          -  Inability to follow procedures due to psychological disorders, dementia or&#xD;
             insufficient&#xD;
&#xD;
          -  Knowledge of project language (German).&#xD;
&#xD;
          -  Participation in another study with investigational drug within the 30 days preceding&#xD;
             and during the present study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Beglinger, MD</last_name>
    <role>Study Chair</role>
    <affiliation>St. Claraspital klinische Forschungsabteilung</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Claraspital</name>
      <address>
        <city>Basel</city>
        <zip>4016</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>November 2, 2016</study_first_submitted>
  <study_first_submitted_qc>November 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2016</study_first_posted>
  <last_update_submitted>August 7, 2018</last_update_submitted>
  <last_update_submitted_qc>August 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

